NO20090057L - Regulatoriske nukleinsyre elementer - Google Patents
Regulatoriske nukleinsyre elementerInfo
- Publication number
- NO20090057L NO20090057L NO20090057A NO20090057A NO20090057L NO 20090057 L NO20090057 L NO 20090057L NO 20090057 A NO20090057 A NO 20090057A NO 20090057 A NO20090057 A NO 20090057A NO 20090057 L NO20090057 L NO 20090057L
- Authority
- NO
- Norway
- Prior art keywords
- elements
- expression
- sequence
- gene
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SAMMENDRAG Det beskrives DNA-sekvenser, spesielt transkripsjons-, resp. ekspresjonsøkende elementer (TE-elementer) og deres anvendelse på en ekspresjonsvektor i forbindelse med en enhancer, en promoter, et produktgen og en seleksjonsmarkør. Videre beskrives Sekvens Nr.1 samt TE-elementene TE-01, -02, -03-, -04, -06, -07, -08, -10, -11 eller -12. Som følge av deres lille dimensjon er TE-06, TE-07 eller TE-08 særlig foretrukket. Sekvens Nr.1 stammer fra en sekvensregion som ligger oppstrøms for den kodende region av Ub/S27a-genet fra CHO-celler. TE-elementer bevirker en ekspresjonsøkning av produktgenet ved stabil integrering i det eukaryote genom, fortrinnsvis CHO-DG-44-genomet. Kromosomale posisjonseffekter blir omgått, avskjermet eller opphevet. Derved økes så vel andelen av høyprodusenter av en transfeksjonsansats som det absolutte ekspresjonsnivå opp til det femtendobbelte.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06117862 | 2006-07-26 | ||
PCT/EP2007/055954 WO2008012142A1 (de) | 2006-07-26 | 2007-06-15 | Regulatorische nukleinsäureelemente |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090057L true NO20090057L (no) | 2009-02-16 |
Family
ID=37441548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090057A NO20090057L (no) | 2006-07-26 | 2009-01-06 | Regulatoriske nukleinsyre elementer |
Country Status (23)
Country | Link |
---|---|
US (3) | US20080124760A1 (no) |
EP (1) | EP2049671B1 (no) |
JP (1) | JP5270544B2 (no) |
KR (1) | KR101485853B1 (no) |
CN (1) | CN101517085B (no) |
AR (1) | AR061472A1 (no) |
AU (1) | AU2007278368B2 (no) |
BR (1) | BRPI0714594A2 (no) |
CA (1) | CA2658595C (no) |
CY (1) | CY1113711T1 (no) |
DK (1) | DK2049671T3 (no) |
EA (1) | EA016880B1 (no) |
ES (1) | ES2401654T3 (no) |
HK (1) | HK1134107A1 (no) |
IL (1) | IL196676A0 (no) |
MX (1) | MX2009000781A (no) |
NO (1) | NO20090057L (no) |
NZ (1) | NZ575115A (no) |
PL (1) | PL2049671T3 (no) |
PT (1) | PT2049671E (no) |
SI (1) | SI2049671T1 (no) |
TW (1) | TW200815591A (no) |
WO (1) | WO2008012142A1 (no) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
KR101993938B1 (ko) | 2011-04-13 | 2019-06-27 | 내셔날 리서치 카운실 오브 캐나다 | IFNα2로부터의 SAR 인자를 갖는 발현 시스템 |
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US9951131B2 (en) | 2013-07-12 | 2018-04-24 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
JP2017501848A (ja) | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | 便秘症状からのレビー小体病の免疫療法のモニター |
CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
JP6728053B2 (ja) | 2014-03-12 | 2020-07-22 | プロセナ バイオサイエンシーズ リミテッド | 抗mcam抗体及び関連する使用方法 |
JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI711631B (zh) | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
RS61924B1 (sr) * | 2015-02-02 | 2021-06-30 | Meiragtx Uk Ii Ltd | Regulacija genske ekspresije putem aptamerom posredovane modulacije alternativnog splajsovanja |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
MY197413A (en) | 2016-05-02 | 2023-06-16 | Prothena Biosciences Ltd | Antibodies recognizing tau |
JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
JP7076711B2 (ja) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
EP3478715A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
CA3076313A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
CA3117816A1 (en) | 2018-11-26 | 2020-06-04 | Forty Seven, Inc. | Humanized antibodies against c-kit |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
JP7412860B2 (ja) | 2020-10-16 | 2024-01-15 | 株式会社奥村組 | 泥水式シールド掘進機および泥水式シールド掘進機における圧縮空気の圧力調整方法 |
AU2022261882A1 (en) * | 2021-04-21 | 2023-12-07 | Janssen Biotech, Inc. | Materials and methods for improved phosphotransferases |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
DE69128037T2 (de) | 1990-11-13 | 1998-05-07 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
US5786166A (en) | 1991-10-25 | 1998-07-28 | University Of Tennessee Research Corporation | Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
DK0873405T3 (da) * | 1996-01-11 | 2005-01-17 | Immunex Corp | Ekspressionsforøgende sekvenselementer (EASE) til eukaryote ekspressionssystemer |
WO2000034319A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
WO2000034326A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
WO2000034325A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
ES2257303T3 (es) | 1999-07-12 | 2006-08-01 | Genentech, Inc. | Vectores de expresion y procedimientos. |
EP1305412A2 (en) | 1999-10-14 | 2003-05-02 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
DE60235616D1 (de) | 2001-04-05 | 2010-04-22 | Millipore Corp | Gesteigerte genexpression |
PT1600510E (pt) | 2001-07-04 | 2007-06-25 | Chromagenics Bv | Sequências de adn com actividade anti-repressora. |
US7344886B2 (en) * | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
DK1567652T3 (da) | 2002-11-29 | 2007-11-26 | Boehringer Ingelheim Pharma | Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler |
DE10256083A1 (de) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
-
2007
- 2007-06-13 US US11/762,240 patent/US20080124760A1/en not_active Abandoned
- 2007-06-14 TW TW096121483A patent/TW200815591A/zh unknown
- 2007-06-15 NZ NZ575115A patent/NZ575115A/en not_active IP Right Cessation
- 2007-06-15 AU AU2007278368A patent/AU2007278368B2/en active Active
- 2007-06-15 JP JP2009521178A patent/JP5270544B2/ja active Active
- 2007-06-15 DK DK07730192.7T patent/DK2049671T3/da active
- 2007-06-15 CN CN2007800359296A patent/CN101517085B/zh active Active
- 2007-06-15 EP EP07730192A patent/EP2049671B1/de active Active
- 2007-06-15 WO PCT/EP2007/055954 patent/WO2008012142A1/de active Application Filing
- 2007-06-15 AR ARP070102632A patent/AR061472A1/es active Pending
- 2007-06-15 PT PT77301927T patent/PT2049671E/pt unknown
- 2007-06-15 CA CA2658595A patent/CA2658595C/en active Active
- 2007-06-15 PL PL07730192T patent/PL2049671T3/pl unknown
- 2007-06-15 EA EA200900212A patent/EA016880B1/ru not_active IP Right Cessation
- 2007-06-15 KR KR1020097004079A patent/KR101485853B1/ko active IP Right Grant
- 2007-06-15 ES ES07730192T patent/ES2401654T3/es active Active
- 2007-06-15 SI SI200731174T patent/SI2049671T1/sl unknown
- 2007-06-15 BR BRPI0714594-2A patent/BRPI0714594A2/pt not_active IP Right Cessation
- 2007-06-15 MX MX2009000781A patent/MX2009000781A/es active IP Right Grant
-
2009
- 2009-01-06 NO NO20090057A patent/NO20090057L/no not_active Application Discontinuation
- 2009-01-22 IL IL196676A patent/IL196676A0/en unknown
-
2010
- 2010-01-28 HK HK10100907.0A patent/HK1134107A1/xx not_active IP Right Cessation
- 2010-07-23 US US12/842,468 patent/US9045776B2/en active Active
-
2013
- 2013-02-21 CY CY20131100160T patent/CY1113711T1/el unknown
-
2015
- 2015-04-29 US US14/699,182 patent/US9708626B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AR061472A1 (es) | 2008-08-27 |
HK1134107A1 (en) | 2010-04-16 |
AU2007278368A1 (en) | 2008-01-31 |
ES2401654T3 (es) | 2013-04-23 |
JP5270544B2 (ja) | 2013-08-21 |
CN101517085B (zh) | 2013-08-07 |
SI2049671T1 (sl) | 2013-04-30 |
PT2049671E (pt) | 2013-01-24 |
US9045776B2 (en) | 2015-06-02 |
EA200900212A1 (ru) | 2009-10-30 |
US20150337333A1 (en) | 2015-11-26 |
JP2009544293A (ja) | 2009-12-17 |
EP2049671B1 (de) | 2012-12-19 |
KR101485853B1 (ko) | 2015-01-23 |
IL196676A0 (en) | 2011-08-01 |
TW200815591A (en) | 2008-04-01 |
CA2658595C (en) | 2016-05-31 |
EP2049671A1 (de) | 2009-04-22 |
KR20090046887A (ko) | 2009-05-11 |
CN101517085A (zh) | 2009-08-26 |
WO2008012142A1 (de) | 2008-01-31 |
EA016880B1 (ru) | 2012-08-30 |
CA2658595A1 (en) | 2008-01-31 |
US20100311121A1 (en) | 2010-12-09 |
BRPI0714594A2 (pt) | 2013-02-19 |
US20080124760A1 (en) | 2008-05-29 |
US9708626B2 (en) | 2017-07-18 |
AU2007278368B2 (en) | 2013-12-19 |
CY1113711T1 (el) | 2016-06-22 |
PL2049671T3 (pl) | 2013-05-31 |
MX2009000781A (es) | 2009-01-29 |
NZ575115A (en) | 2011-10-28 |
DK2049671T3 (da) | 2013-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090057L (no) | Regulatoriske nukleinsyre elementer | |
Kong et al. | PHB3 maintains root stem cell niche identity through ROS-responsive AP2/ERF transcription factors in Arabidopsis | |
Gavazzi et al. | A functional sequence-specific interaction between influenza A virus genomic RNA segments | |
Fechter et al. | Recognition of mRNA cap structures by viral and cellular proteins | |
Smith et al. | Inhibition of heat-shock protein 90 reduces Ebola virus replication | |
Álvarez et al. | Mitochondrial sulfide detoxification requires a functional isoform O-acetylserine (thiol) lyase C in Arabidopsis thaliana | |
Gultyaev et al. | Influenza virus RNA structure: unique and common features | |
García-Dorival et al. | Elucidation of the cellular interactome of Ebola virus nucleoprotein and identification of therapeutic targets | |
MX2009003090A (es) | Genes novedosos relacionados con ciclasa de glutaminilo. | |
WO2007002008A3 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells | |
Nishimori et al. | Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila | |
DE50311850D1 (de) | Konstrukte und verfahren zur regulation der genexpression | |
AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
Huang et al. | The Mediator kinase module serves as a positive regulator of salicylic acid accumulation and systemic acquired resistance | |
PE20120115A1 (es) | Composiciones y metodos para inhibir la expresion de genes del factor vii | |
Wang et al. | Polymorphisms in cis‐elements confer SAUR26 gene expression difference for thermo‐response natural variation in Arabidopsis | |
Widjaja et al. | Competition between influenza A virus genome segments | |
EP2557167A3 (en) | Cambium/Xylem-preferred promoters and uses thereof | |
Prochazkova Schrumpfova et al. | Role of HMGB proteins in chromatin dynamics and telomere maintenance in Arabidopsis thaliana | |
AR068529A1 (es) | Uso de clec1b (lecitina tipo c de familia de dominio i, miembro b) | |
Dalakouras et al. | A chimeric satellite transgene sequence is inefficiently targeted by viroid-induced DNA methylation in tobacco | |
CA3058540A1 (en) | Nucleic acid modification and identification method | |
Rodriguez et al. | Mutations of the segment-specific nucleotides at the 3’end of influenza virus NS segment control viral replication | |
Zhang et al. | Fundamental contribution and host range determination of ANP32 protein family in influenza A virus polymerase activity | |
Lee et al. | Construction and characterization of an aureusvirus defective RNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |